NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ten63 Therapeutics

Ten63 Therapeutics

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://ten63tx.com/

Last Round

Strategic

Feb 19, 2026

Total Funding Raised

$72.75M

Company Overview

Ten63 Therapeutics is a biotechnology company that develops small molecule therapeutics for challenging disease targets, primarily in oncology, using its proprietary AI-driven drug discovery platform, BEYOND.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

drug discoveryAI drug discoverysmall-molecule therapeuticscomputational drug discoveryundruggable targetsquantum chemistry modeloncology therapeuticsgenerative chemistryin silico drug designtarget identificationbiotech startupphysics-based modelingdrug resistancepharma partnershipsAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ten63 Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Ten63 Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ten63 Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicFeb 19, 2026
StrategicFeb 19, 2026
Series AMay 2, 2023
SeedJan 27, 2021
AcceleratorJun 25, 2019
Seed
Apr 5, 2019

Key People

Founding team and executive leadership

Mark Hallen

Co-founder And CTO

Founding Team

Marcel Frenkel

Chief Executive Officer, Founder

Founding Team

Ten63 Therapeutics Investors

Notable investors and investment history

Ten63 Therapeutics investors
InvestorRounds
Hatteras Venture PartnersStrategic, Series A
Gates FoundationStrategic
Chugai Venture FundStrategic
RYSE Asset ManagementStrategic
Panorama Point PartnersStrategic
K5 GlobalStrategic
Bill & Melinda Gates FoundationStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 25, 2019

    $250K round from SOSV and IndieBio

Ten63 Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ten63 Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ten63 Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range32
Year Founded2018
Last FundingFeb 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.